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Abstract 
Bardet-Biedl syndrome is a rare autosomal recessive multi-system disease 
characterised by retinal dystrophy, renal malformation, obesity, intellectual disability, 
polydactyly and hypogonadism.  Nineteen disease causing genes (BBS1-19) have 
been identified of which mutations in BBS1 are most common in North America and 
Europe.  
A hallmark of the disease, renal malformation is heterogeneous and is a cause of 
morbidity and mortality through the development of chronic kidney disease. We 
studied the prevalence and severity of chronic kidney disease in the largest reported 
cohort of patients with Bardet-Biedl syndrome-related renal disease, further 
elucidating the phenotype and identifying risk indicators.  
Results from 350 patients attending the UK national Bardet-Biedl syndrome clinics 
were analysed. Thirty one per cent of children and 42% of adults had chronic kidney 
disease. Eight percent of adults had stage 4-5 chronic kidney disease. In childhood, 
renal disease was primarily detected within the first year of life and stage 4-5 chronic 
kidney disease was present in 6%. Fifty one percent of patients had structural renal 
abnormalities on ultrasonography and 35% were hypertensive. These risk factors 
also correlated statistically with chronic kidney disease stages 3b-5.   
Genotype and mutation type were statistically significant risk indicators. Mutations in 
BBS1 or two missense mutations were associated with less severe or lack of chronic 
kidney disease in comparison to mutations in BBS10 or two truncating mutations. 
This study describes the largest reported cohort of patients with renal disease in 
Bardet-Biedl syndrome and identifies risk factors to be considered in genetic 
counselling. 
Introduction 
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy characterised 
by rod cone dystrophy, renal malformations, learning difficulties, obesity, post-axial 
polydactyly and hypogonadism.1 Nineteen disease causing genes have been 
identified (BBS1-BBS19) in the last two decades. BBS genes code for proteins that 
localise to the cilia or the basal body and are thought to be involved in cilia 
development and maintenance2. Mutations in BBS genes lead to defective cilia. 
Sequencing of known disease causing genes confirms a clinical diagnosis of BBS in 
around 80% of patients2. Variable expressivity is a hallmark of BBS and both inter- 
and intrafamilial phenotypic variation is observed.2  
Structural renal and urinary tract anomalies and renal dysfunction is a cause of 
considerable morbidity and reported to affect 53-82% of patients with BBS.2-6 The 
primary renal phenotype is highly variable ranging from cystic tubular disease, 
dysplastic renal disease and focal segmental glomerulosclerosis to concentrating 
defects.3-7 Lower urinary tract dysfunction is observed in many patients and may 
have upper renal tract sequelae.8  It is thought that ciliary dysfunction leads to 
disturbance of the non-canonical Wnt signalling pathway which may contribute to the 
development of cystic kidney disease classically associated with BBS.2 Secondary 
renal disease may occur as a consequence of hypertension and diabetes which are 
frequently observed in this population. 
The high frequency of renal disease in BBS is a cause of great anxiety among 
patients due to the devastating effect this can have on quality of life, morbidity and 
mortality.4-6 This study examines renal disease in the largest reported cohort of BBS 
patients and identifies indicators of disease which are directly relevant to patient 
management and clinical stratification.    
 
Results 
Overview of the BBS population 
Three hundred and fifty patients attended the adult and paediatric national BBS 
clinics in Birmingham and London over a four year period (2010-14).  The patient 
population ranged in age from birth to 60 years old, with a peak frequency in the six 
to ten year old category, and with few older adults. 
Diagnosis was based on clinical phenotyping. All patients underwent genetic testing. 
On sequencing 13 disease related genes, molecular confirmation of the diagnosis 
was achieved in 80% of all pedigrees (216 of 270) and in 77% of all patients (265 of 
350). A full list of genotypes can be found in supplemental table 1. The gender 
distribution was 54% male and 46% female. Sixty nine per cent of patients were 
Caucasian, 28% South East Asian and the remaining 3% had a mixture of other 
backgrounds (African, Chinese and Ashkenazi Jewish).  
 The distribution of genotypes is demonstrated in figure 1. For the purpose of 
statistical analysis mutation type was classified according to severity. One hundred 
and twenty five patients had two missense mutations, eighty two had two truncating 
mutations (nonsense, frameshift, splice site or a combination), 39 had a combination 
of missense and truncating mutations and the remaining nineteen patients had other 
mutation combinations, including exon deletions and start codon aberrations.  
  
Age of onset of renal disease 
One hundred and fifty six paediatric patients were seen in the paediatric clinics.  Of 
these we were able to retrospectively obtain the earliest recorded age of onset of 
Chronic Kidney Disease (CKD) stage9 2-5 in 49 paediatric patients attending the 
BBS clinic (figure 2).  All paediatric patients with CKD4-5 were diagnosed before the 
age of 5. The majority of patients with any stage of CKD presented before the age of 
10. Since the peak referral age to the clinic is late childhood, later recorded onset of 
CKD is likely to reflect significant ascertainment bias as patients may have 
asymptomatic renal disease and no previous renal sonography. 
Observations from the national BBS clinics suggest that patients either develop 
CKD4-5 in childhood or maintain normal or near-normal renal function into 
adulthood. Figure 3 demonstrates that frequency of CKD4-5 remains similar in adults 
and children (8% and 6% respectively).  
 
Prevalence of chronic renal disease 
Estimated GFR (eGFR) results were available for 189 adults and 133 paediatric 
patients. Seventy per cent of adult patients had at least two eGFR readings. The 
prevalence of each stage of CKD in adults and children is demonstrated in figure 3 
where CKD2-5 is present in 42% and 31% respectively. In the adult population 
(n=194) 107 patients were considered free of renal disease or had CKD1, and five 
did not have an eGFR or a renal ultrasounds scan. Forty three adult patients had a 
normal renal ultrasound scan and 47 had a structural abnormality. In the paediatric 
population (n=156) 84 patients were considered free of renal disease or had CKD1, 
and 23 patients did not have an eGFR. Eighty seven paediatric patients had a renal 
ultrasound scan, 43 of which revealed a structural abnormality. Nine patients had 
neither a documented eGFR or ultrasound scan. All patients were requested to 
provide a sample for urinalysis. Ninety per cent of children and 96% of adults 
respectively were able to comply. Urinalysis was normal in all those considered free 
of renal disease. Tables 1a and 1b demonstrate the number of patients seen in the 
adult and paediatric clinics and the prevalence of CKD indicators. Tables 2a and 2b 
demonstrate the prevalence of CKD stages 2-5 in the adult and paediatric 
populations presenting to the Bardet-Biedl syndrome clinics.  
The age at which patients reached CKD5 is known for 20 patients in this cohort. Of 
these patients 70% (n=14) had reached CKD5 by the age of 20. The age of onset of 
CKD5 was delineated retrospectively and Kaplan-Meier survival to CKD5 is 
demonstrated in figure 4.  
Genotype and mutation type analyses in adults with BBS revealed statistically 
significant correlations with the presence of severe renal disease defined as CKD 
stage 3b to 5 (eGFR<45 ml/min/1.73m2).  Univariable logistical regression analysis 
indicated that mutations in BBS2, BBS10 and BBS12 were more likely to be 
associated with severe renal disease than mutations in BBS1 (p values: 0.02, 
0.0003, 0.03 respectively) (table 3).  Univariable logistical regression analysis of 
mutation type revealed that truncating mutations and truncating/missense mutations 
were statistically associated with severe renal disease in comparison to two 
missense mutations (p values= 0.000003, 0.01 respectively) (table 3).   
Proportional frequencies of CKD stages 2, 3, 4 and 5 in adults were compared for 
the commonest genotypes BBS1 and BBS10 as outlined in figure 5.  Patients with 
BBS1 mutations are more likely to be disease free or have early stage CKD. 
Mutations in BBS10 were more frequently represented with increasing stage of CKD. 
Of note, patients attending our clinics with mutations in BBS1 are statistically 
significantly older than those with mutations in BBS10 (p=0.0011).  
 Previous research indicates that the recurring missense mutation M390R in BBS1 
may be hypomorphic.10;11 We assessed this by comparing adult patients who were 
homozygous for M390R to patients with other mutation types in BBS1 (supplemental 
figure 1). This did not reveal an obvious hypomorphic effect of homozygous BBS1 
M390R mutations. It may reflect the relatively small group of patients, or that the 
majority of patients with mutations in BBS1 who are not homozygous for M390R are 
heterozygous for this mutation. Since BBS is an autosomal recessive disease, it is 
possible that the the hypomorphic effect of M390R predominates even in those who 
are heterozygous. Of note, only one patient homozygous for BBS1 M390R had 
progressed beyond stage 3 CKD. The patient presented following renal transplant 
aged 23 to our service and the cause of renal failure was unclear although presumed 
to be a result of BBS.  
We assessed for the presence of micro- and macroalbuminuria by analysing urinary 
albumin/creatinine ratios as a proxy for glomerular injury. Urinary albumin/creatinine 
ratios were available for 139 adult and paediatric patients. Seven (5%) had 
proteinuria (defined as urinary albumin/ creatinine >30 mg/mmol); three of whom 
were diabetic. Thirty two patients (28%) had microalbuminuria (defined as urinary 
albumin/ creatinine >3.5 mg/mmol12), and two of these patients were diabetic. This 
could be matched to an eGFR in 119 patients. There was a statistically significant 
correlation between severe renal disease and urinary albumin/ creatinine ratios (p= 
0.006).  The sample size was inadequate for correlation with genotype and mutation 
type.  
Although under-reported, 6% of the adult BBS population report urological 
complications requiring specialist management. Urological abnormalities include 
neuropathic bladder, vesico-ureteric reflux, urinary incontinence and bladder outflow 
obstructions. 
 
Presence of structural abnormalities 
One hundred and seventy seven ultrasound reports from the entire cohort were 
available for our assessment. Eighty seven were unremarkable and 90 revealed 
structural defects. Abnormalities were categorised as atrophic/scarring, echogenic or 
loss of corticomedullary differentiation, cystic or dysplastic, other developmental 
abnormality or hydronephrosis as seen in figure 6. No consistent pattern was evident 
in the type of renal structural aberrations observed; patients with cystic disease 
ranged from unilateral single cysts to multiple bilateral cystic disease. Developmental 
abnormalities included horseshoe kidneys, ectopic kidneys, duplex and absent 
kidneys. Where several abnormalities were present, the predominant structural 
defect is reported. On assessing genotype correlations (BBS1 versus BBS10) no 
association with the presence of structural abnormality was identified (p=0.188).  
Correlating the presence of all causes of structural abnormality in adults with CKD 
staging revealed a strong correlation with CKD at stage 3b-5 (p=0.039). All patients 
with a reported renal ultrasound scan and severe renal disease had a detectable 
structural abnormality (n=7).  
Ultrasound reports from 39 paediatric patients with known renal structural 
abnormalities who had both antenatal and postnatal sonography failed to identify the 
anatomical aberration prenatally in 14 patients (36%). 
Five paediatric patients had abnormal antenatal renal ultrasound reports and normal 
postnatal sonography. In all cases, non-specific echogenicity was reported 
antenatally and no specific structural abnormalities were detected.  
In this cohort, 30 patients presented with sonographic evidence of cystic kidney 
disease which is classically associated with BBS. Twenty four of these patients had 
molecular confirmation of BBS. Patients with mutations in BBS1 and BBS10 
accounted for the majority of genotypes represented (42% and 21% respectively).  
Figure 7 demonstrates some of the structural renal aberrations commonly detected 
on ultrasonography. 
 
Hypertension and diabetes 
Thirty five per cent of adult patients (n=67) in this cohort were hypertensive. There is 
a statistically significant correlation between CKD3b-5 and the presence of anti-
hypertensive medication (p=0.003) (table 3).  There was a significant association 
between the presence of hypertension and albuminuria (p=0.0009). The most 
commonly prescribed antihypertensive medications were angiotensin-converting-
enzyme inhibitors (52%) followed by diuretics (21%), calcium channel blockers 
(15%), beta blockers (8%) and angiotensin receptor blockers (3%).   
Fifteen per cent of adult patients (n=28) were on hypoglycaemic medication. There 
was no statistically significant association with CKD3b-5 (p=0.471).  
 Discussion 
To our knowledge, this is the largest reported study characterising the renal 
phenotype in BBS. The age distribution of our patient population is most likely a 
reflection of a number of factors affecting patient referral. Children are often referred 
to the service following the onset of visual decline which typically occurs towards the 
end of the first decade of life, accounting for the high frequency of children aged six 
to ten years old. Many children presenting in the first year of life are siblings of 
patients known to the service. The clinical service has been in operation since 2010 
and patients over the age of 60 may not have a known diagnosis of BBS, as 
familiarity with the syndrome has only increased in the last two decades. The 
variation of genotypes presented in this study reflects the UK BBS population and is 
similar to that observed by others in Europe and North America.13;14 Patients with 
mutations in BBS1 generally present later to the BBS clinics than patients with 
mutations in BBS10. This may relate to a milder phenotype and later onset of retinal 
degeneration. 
 
Our study suggests that the onset of primary renal disease in children predominantly 
occurs in infancy. For many adult patients it was difficult to accurately determine the 
age of onset of renal disease since patients with CKD are managed locally with an 
annual specialist BBS review. A striking observation is the relatively modest 
difference in prevalence of CKD4-5 between adults (8%) and children (6%) (figure 
3). This supports our hypothesis that patients with BBS primarily either develop 
CKD4-5 in childhood or remain entirely or relatively free of severe renal disease. The 
small proportion of adult onset severe renal disease may relate to co-morbidities 
associated with BBS such as urological complications, hypertension, obesity and 
diabetes.  These are potentially modifiable risk factors which should be managed 
appropriately. The number of patients over the age of 30 is limited in this study and it 
is therefore not possible to draw statistically significant conclusions about the risk of 
developing renal disease in older BBS patients. 
The prevalence of CKD in this cohort is lower than anticipated based on previous 
estimates3. Forty two per cent of adults have CKD stage 2-5 and only 8% of adult 
patients develop CKD3b-5. There appears to be both genotype and mutation type 
correlations with CKD with increased risk of developing CKD3b-5 for those patients 
who have truncating mutations and mutations in BBS10. This is in keeping with  a 
previous study indicating similar findings for cardiovascular risk factors in this 
group.15 However, it is difficult to ascertain if genotype and mutation type represent 
independent risk factors or if statistical significance of mutation types reflects the 
high prevalence of missense mutations in BBS1 and truncating mutations in other 
genotypes. Only one of the patients in this study with homozygous BBS1 M390R 
mutations developed CKD5. BBS1 M390R is the most common mutation observed in 
the BBS population in Europe and Northern America and patients homozygous for 
M390R make up a significant proportion of the patient population (45% of the UK 
population are homozygous or heterozygous for this mutation, own unpublished 
data). This significant subgroup of patients could be counselled regarding their lower 
risk of progressing to CKD4-5.   
Guidelines for the management of BBS recommend that every patient should have a 
baseline renal ultrasound examination to assess for the presence of any structural 
abnormalities.16  Although some patients who have abnormal renal ultrasound scans 
do not go on to develop CKD, there is a statistically significant correlation between 
structural abnormalities and CKD. This study validates the requirement for a baseline 
postnatal renal ultrasound scan following a diagnosis of BBS. Structural abnormality 
should alert clinicians that close monitoring is required to identify any deterioration in 
renal function. Anecdotal reports of structural renal abnormalities present antentally 
and absent on postnatal sonography could not be confirmed in this study.  
One report17 suggests that mutations in BBS10 are associated with antenatal severe 
cystic kidney disease which is incompatible with life. In this study, the prevalence of 
BBS10 mutations among patients presenting with postnatal sonographic evidence of 
cystic kidney disease (21%, n=5) was consistent with that of the overall study 
population (20%).  The authors are not aware of a higher rate of pregnancy losses in 
families with BBS10 mutations. 
It has previously been suggested that proteinuria is consistently absent in BBS –
associated renal disease.18 This study demonstrates the co-existence of proteinuria 
and CKD and the correlation between CKD3b-5 and albuminuria, and is likely the 
results of renal mass reduction caused by structural abnormalities. 
We have previously reported on the high prevalence of anti-hypertensive medication 
in this group10. It is not clear if the statistical correlation between CKD and anti-
hypertensive medication is related to anti-hypertensive agents prescribed as a part 
of CKD management to decrease the rate of progression or if hypertension 
represents an independent statistical risk factor in this cohort. 
In summary, this study maps the prevalence of renal disease in BBS and 
characterises the highly variable renal phenotype. We have identified risk indicators 
as well as potentially protective factors for renal disease. Adults who harbour 
missense mutations in BBS1 and have normal renal ultrasound scans in adulthood 
are less likely to develop CKD3b-5. Patients with truncating mutations in BBS10, 
hypertension and abnormal renal ultrasound scans are at significantly increased risk 
of CKD3b-5 compared to the general BBS population.  Primary renal disease as a 
consequence of BBS appears to present in early childhood.  
The evidence presented here could have a direct clinical implication for BBS 
patients. The presence or absence of risk factors should be considered when 
counselling patients and may be used to stratify the clinical service. Previous 
recommendations advise that patients should be reviewed by a nephrologist 
annually unless CKD is present in which case closer monitoring is required. Based 
on this study the authors suggest that adults with the lowest risk of renal disease 
could receive community nephrology follow up and low risk children could be seen 
less frequently in specialist clinics. All patients with end stage renal disease require 
frequent specialist follow up and those with identifiable risk factors or early stable 
renal disease (CKD1-3) warrant annual specialist follow up.  A multi-national study 
could facilitate the development of a statistical renal risk calculator for this unique 
population. 
 
Concise methods 
Patients 
The following renal parameters were ascertained retrospectively for all 350 patients 
attending the national BBS clinics: known history of renal disease, stage of CKD if 
present, any abnormalities noted on renal ultrasound scanning, estimated glomerular 
filtration rate (eGFR), renal function tests and relevant concomitant factors including 
presence of hypertension, diabetes and obesity. All subjects gave informed consent 
or assent. Patients were seen in the paediatric clinics if they were 16 years of age or 
under, or 18 years of age or under and in full time education. All other patients were 
seen in the adult clinics.  All blood and urinary tests were completed following a six 
hour starvation period. The Modification of Diet in Renal Disease (MDRD) formula 
was applied to estimate glomerular filtration rate in all adults in keeping with its 
common use for patients with obesity and diabetes in the general population19.  
Estimated GFR for the paediatric population was calculated according the Schwarz-
Haycock formula (height (cm) x 31/ creatinine (µmol/l)).  Adults were categorised as 
hypertensive if they were on anti-hypertensive medication, or if they fulfilled the 
criteria for antihypertensive treatment in diabetic patients according to Kidney 
Disease Improving Global Outcomes (KDIGO) guidelines20. Referrals were made 
primarily from the British national patient support group, clinical geneticists and 
ophthalmologists in the United Kingdom.  
 
Mutation analysis 
Mutation analysis was undertaken through the UK national BBS gene panel which 
encompasses 11 BBS genes including BBS1- BB10 and BBS12 as well as two BBS 
associated genes MKS1 and ALMS1.  
 
Statistical analysis 
Genotype-phenotype analysis was targeted to patients with mutations in the two 
most commonly affected genes: BBS1 and BBS10, as well as the less common 
genotypes BBS2 and BBS12 where adequate sample sizes were available.  
Correlation with mutation type was also assessed. Patients with two known 
missense mutations were compared with two known truncating (nonsense or 
frameshift) mutations and a combination of missense/truncating mutations. The 
nonparametric Mann–Whitney U test was performed to assess differences in median 
age for genotypes BBS1 and BBS10. For the purpose of genotype and mutation type 
analysis children were not included since renal failure appears to occur and progress 
primarily in childhood, hence CKD stage was not considered to be stable until 
adulthood.  Multivariable regression analysis was applied to evaluate genotype-
phenotype analysis and assess the effect of confounders on chronic renal disease. 
The relative burden of each risk factor was described in odds ratios. Statistical 
analyses were conducted in R (R Core Team (2013). R: A language and 
environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. Retrieved from: http://www.R-project.org/). A 5% confidence level 
was considered statistically significant. All tests were two tailed. 
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Figure legends 
Figure 1. Distribution of genotypes.  
Figure 2. Age at which renal disease (CKD2-5) was first noted in paediatric patients 
with BBS (n=49). 
Figure 3. Distribution of chronic kidney disease stages in (a) adults (n=194) and (b) 
children (n=156). 
Figure 4. Kaplan Meier survival curve:  Age at which patients were first diagnosed 
with CKD5 (n=350).  
Figure 5. Percentage distribution of chronic kidney disease stages in adults. 
Mutations in BBS1 versus BBS10; Absolute numbers are indicated above each 
column. 
Figure 6. Prevalence of structural abnormalities detected on sonography. 
Figure 7. Renal ultrasound images demonstrating common structural abnormalities 
associated with Bardet-Biedl syndrome. A: Demonstrates the typical cystic dysplastic 
appearance associated with BBS: A small subcortical cyst, one large cyst and loss of 
corticomedullary differentiation. B:  Subcapsular cysts and increased echogenicity. 
C: Nephrocalcinosis. D: Renal pelvic dilatation.  
Supplemental figure 1. Percentage distribution of chronic kidney disease stages in 
adults. BBS1 M390R vs other BBS1 mutation types. Absolute numbers are indicated 
above each column.  
Table 1: Chronic kidney disease assessment in the adult (A) and paediatric 
population (B). 
1A: Chronic kidney disease in patients attending the adult clinic 
Chronic Kidney Disease marker Number/ total (% of 
total) 
Total no. of patients 194 (100%) 
eGFR Total no. of patients who had eGFR 189/194 (97%) 
  Normal or CKD1 107/ 189 (57%) 
  CKD2-5 (<90ml/min/1.73m2) 82/189 (43%) 
   CKD5 (<15ml/min/1.73m2) 12/189 (8%) 
Renal USS  90/194 (46%)  
 Normal 43/90 (48%) 
 Abnormal 47/90 (52%) 
No USS 
and no 
eGFR 
 5/194 (3%)  
Urinalysis  186/194 (96%)  
 
 
1B: Chronic kidney disease in patients attending the paediatric clinic 
Chronic Kidney Disease marker Number/ total (% of 
total) 
Total no. of patients 156 (100%) 
eGFR Total no. of patients who had eGFR 133/156 (86%) 
  Normal or CKD1(>90ml/min/1.73m2) 84/133 (63%) 
  CKD2-5 (<90ml/min/1.73m2) 49/133 (37%) 
   CKD5 (<15ml/min/1.73m2) 8/133 (5%) 
Renal USS Total 87/156 (55%) 
  Normal 44/87 (51%) 
  Abnormal 43/87 (49%) 
No USS 
and no 
eGFR 
 9/156 (6%) 
Urinalysis  140/156 (90%) 
 
Table 2. Prevalence of chronic kidney disease in adults (A) and children (B) 
according to age group.  
2A: Prevalence of chronic kidney disease in patients attending adult clinics. 
Absolute numbers (percentage) 
Age 
group 
Normal/ CKD1/ 
No eGFR 
CKD2 CKD3 CKD4 CKD5 Total 
16-20 27 0 3 0 2 32 
21-25 29 5 1 1 3 39 
26-30 17 5 1 1 1 25 
31-35 14 4 1 1 3 23 
36-40 6 7 5 0 1 19 
41-45 5 8 2 1 1 17 
46-50 6 5 2 0 1 14 
51-55 6 8 3 0 0 17 
56-60+ 2 5 1 0 0 8 
Total 112 (58%) 47 (24%) 19 (10%) 4(2%) 12 (6%) 194 
 
2B: Prevalence of chronic kidney disease in patients attending paediatric 
clinics. Absolute numbers (percentage) 
Age 
group 
Normal/ CKD1/ 
no eGFR 
CKD2 CKD3 CKD4 CKD5 Total 
0-5 22 2 7 0 5 36 
6-10 42 7 5 2 1 57 
11-15 29 6 2 0 1 38 
16-18 14 9 1 0 1 25 
Total 107 (69%) 24 (15%) 15 (10%) 2 (1%) 8 (5%) 156 
 
  
Table 3. Univariable logistical regression analysis of risk factors for severe renal 
disease (eGFR<45 ml/min/1.73 m2) in adults with known common genotypes. All 
statistically significant findings are highlighted in bold. 
Risk factors for severe renal disease  (n=154) 
Risk factor Odds ratio Confidence 
interval 
2.5%              97.5% 
P value 
Genetic factors     
 Genotype (n=154)     
      - BBS1 mutation (n= 90) (Reference)    
     - BBS2 mutation (n=22) 4.4 1.28 15.19 0.016 
      - BBS9 mutation (n=6) 2.4 0.12 17.74 0.458 
     - BBS10 mutation (n=26) 7.4 2.49 23.32 0.0003 
     - BBS12 mutation (n=10) 5.9 1.08 28.39 0.0278 
 
 Mutation type (n=149) 
    
     - Missense/ missense (n=76) (Reference)    
     - Truncating/ truncating (n=40) 11.4 3.9 41.8 3.43e-05 
     - Missense/truncating (n=33) 6.3 1.5 28.6 0.0116 
Diabetes (n=137) 0.62 0.14 0.99 0.471 
Hypertension (n=137) 5.43 2.21 14.29 0.003 
BMI (n=93) 1.04 0.96 1.10 0.321 
Age (n=154) 1.02 0.99 1.96 0.154 
 
  
Supplemental table 1: List of known BBS genotypes, mutation types and protein 
changes 
